This is the last of our conference previews for #ESMO17 – after this we move on to the emerging data coming out from Madrid.
Most of the attention is rightly focused on the big phase 3 trial readouts that are eagerly expected, but what about some of the hidden gems from smaller companies?
What new IO and immunotherapies are looking interesting this year?
We have five such highlights for readers to watch out for. Things should get quite interesting over the next week or so.